48 completed, 8 terminated, 6 recruiting, 4 unknown. 70 Phase 2, 11 Phase 1, 2 Phase 3.
Follow Cough: new trials by email Literature Review of Cough trials Research Report on Cough
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Mechanisms of Change in Behavioral Cough Suppression Therapy for Refractory Chronic Cough BCS+inactive, BCS+active - Chronic Cough (CC), Refractory Chronic Cough | Phase 2 | Recruiting | University of Montana | 135 | 2026-08-13 | 2026-08-18 |
| A Study to Investigate the Efficacy and Safety of SC0032, a Magnesium Salt Oral Spray, in Adults With Refractory or Unexplained Chronic Cough SC0032, Placebo - Refractory Chronic Cough and Unexplained Chronic Cough | Phase 2 | Recruiting | Sensory Cloud, Inc. | 60 | 2026-07-13 | 2026-10-14 |
| The Effect of Nalbuphine Extended-Release (NAL ER) on Cough in Participants With Refractory Chronic Cough (RCC) NAL ER, Placebo - Refractory Chronic Cough | Phase 2 | Recruiting | Trevi Therapeutics | 100 | 2026-06-22 | 2026-11-05 |
| Study to Investigate the Efficacy and Safety of Apomivir® Apomivir®, Placebo - Influenza | Phase 2 | Not yet recruiting | Far East Bio-Tec Co., Ltd | 196 | 2026-05-31 | 2025-05-14 |
| A Phase 2 Study of HW091077 in Participants With Refractory Chronic Cough Or Unexplained Chronic Cough (RCC/UCC). HW091077, Matching placebo to HW091077 - Refractory Chronic Cough | Phase 2 | Not yet recruiting | Hubei Bio-Pharmaceutical Industrial Technological Institute Inc. | 180 | 2026-05-01 | 2026-03-19 |
| Air Versus Lignocaine for Endotracheal Tube Cuff Inflation and Effect on Postoperative Sore Throat and Intracuff Pressure Xylocaine - Postoperative Sore Throat, Cough, Hoarseness | Phase 2 / Phase 3 | Active not recruiting | PAEC General Hospital, Islamabad | 80 | 2025-08-02 | 2026-01-02 |
| Medical Herbs Inhibit Inflammation Directing T Cells to Kill the COVID-19 Virus (COVID) Inflammation (I), Inflammation (II), Inflammation (III) - Covid19 Virus Infection | Phase 1 / Phase 2 | Recruiting | All Natural Medicine Clinic, LLC | 100 | 2025-01-01 | 2025-02-19 |
| Safety and Efficacy Reconyl for Cough With/Without Sore Throat Reconyl, Placebo tablet of Reconyl - Cough | Phase 2 | Completed | Dexa Medica Group | 60 | 2024-07-23 | 2025-02-07 |
| Efficacy and Safety of ME-015 (Suplatast Tosilate) in Cough Related to Idiopathic Pulmonary Fibrosis (COSMIC-IPF) ME-015 (Suplatast Tosilate), Identical placebo - Idiopathic Pulmonary Fibrosis, Cough | Phase 2 | Active not recruiting | Melius Pharma AB | 40 | 2024-04-01 | 2025-04-09 |
| A Study of HS-10383 in Chinese Adult Subjects With Refractory or Unexplained Chronic Cough (RUCC) HS-10383, HS-10383 Placebo - Cough | Phase 2 | Unknown | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 276 | 2024-03-01 | 2024-03-04 |
| Cough Reduction in IPF With Nalbuphine ER NAL ER, Placebo - Idiopathic Pulmonary Fibrosis | Phase 2 | Completed | Trevi Therapeutics | 165 | 2024-02-06 | 2026-06-26 |
| A Phase Ib/II Clinical Study in Patients With Refractory Chronic Cough TCR1672 tablet - Refractory Chronic Cough | Phase 1 / Phase 2 | Unknown | Beijing Tide Pharmaceutical Co., Ltd | 72 | 2024-02-01 | 2024-01-19 |
| Refractory Chronic Cough Improvement Via NAL ER (RIVER) NAL ER, Placebo - Refractory Chronic Cough | Phase 2 | Completed | Trevi Therapeutics | 66 | 2023-11-30 | 2026-03-30 |
| QR052107B Tablets in Patients With Subacute Cough of Phase Ⅱ Study QR052107B 100 mg, QR052107B 400 mg, Placebo - Cough | Phase 2 | Completed | Wuhan Createrna Science and Technology Co., Ltd | 270 | 2023-06-21 | 2025-04-10 |
| A Study to Assess the Efficacy and Tolerance of HRS-2261 in Subjects With Refractory Chronic Cough HRS-2261 oral tablet, Matching placebo to HRS-2261 - Refractory Chronic Cough | Phase 2 | Completed | Guangdong Hengrui Pharmaceutical Co., Ltd | 97 | 2023-03-09 | 2026-01-21 |
| Bolus vs. Continuous IV Lidocaine Against Post-Extubation Cough in Post-Thyroidectomy Patients Lidocaine IV - Cough | Phase 2 | Completed | Universitas Padjadjaran | 40 | 2023-02-02 | 2023-09-22 |
| Efficacy and Safety Study of Orvepitant for Chronic Cough in Patients With Idiopathic Pulmonary Fibrosis Orvepitant Maleate, Placebo - Cough, Idiopathic Pulmonary Fibrosis | Phase 2 | Completed | Nerre Therapeutics Ltd. | 80 | 2022-08-01 | 2025-11-10 |
| A Clinical Trial to Evaluate the Safety and Efficacy in Subjects With Chronic Cough ADX-629, Placebo - Chronic Cough | Phase 2 | Completed | Aldeyra Therapeutics, Inc. | 51 | 2022-04-07 | 2025-02-28 |
| Efficacy of Two Doses of Duloxetine & Amitriptyline in Interstitial Lung Disease-related Cough Amitriptyline 25 MG, Amitriptyline 50 MG, Duloxetine 30 MG - Interstitial Lung Disease | Phase 2 | Recruiting | Mayo Clinic | 25 | 2021-11-01 | 2026-01-21 |
| Efficacy of Two Doses of Duloxetine and Amitriptyline in Subjects With Refractory Chronic Cough Duloxetine 30 MG, Duloxetine 60 MG, Amitriptyline 25 MG - Refractory Chronic Cough | Phase 2 | Recruiting | Mayo Clinic | 50 | 2021-11-01 | 2026-01-21 |
Showing 20 of 70. Sign in to see all of them.
Chronic Cough (33) · Idiopathic Pulmonary Fibrosis (6) · Dyspnea (3) · Fever (3) · Parkinson Disease (3) · Pharyngitis (3) · COVID-19 (2) · Deglutition Disorders (2) · Dizziness (2) · Fibrosis (2) · Hypertension, Pulmonary (2) · Inflammation (2) · Lung Diseases, Interstitial (2) · Pulmonary Arterial Hypertension (2)
Pathological Conditions, Signs and Symptoms (70) · Respiration Disorders (70) · Respiratory Tract Diseases (70) · Signs and Symptoms (70) · Signs and Symptoms, Respiratory (69) · Lung Diseases (15) · Nervous System Diseases (9) · Pathologic Processes (8) · Lung Diseases, Interstitial (7) · Infections (6) · Otorhinolaryngologic Diseases (6) · Pulmonary Fibrosis (6) · Respiratory Tract Infections (6) · Central Nervous System Diseases (5)
Gefapixant (8) · Capsaicin (4) · Nalbuphine (4) · 8-(bis(2-chlorophenyl)methyl)-3-(2-pyrimidinyl)-8-azabicyclo(3.2.1)octan-3-ol (2) · Amitriptyline (2) · BLU-5937 (2) · Duloxetine Hydrochloride (2) · Lidocaine (2) · ADX-629 (1) · Acetylcysteine (1) · Albuterol (1) · DNK 333 (1) · Dosage Forms (1) · GSK2798745 (1) · Hesperidin (1)
Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (7) · Merck Sharp & Dohme LLC (4) · Trevi Therapeutics (4) · University of Florida (4) · Bayer (3) · Bellus Health Inc. - a GSK company (2) · GlaxoSmithKline (2) · Mayo Clinic (2) · Novartis (2) · Novartis Pharmaceuticals (2) · Ainos, Inc. (f/k/a Amarillo Biosciences Inc. (1) · Aldeyra Therapeutics, Inc. (1) · Algernon Pharmaceuticals (1) · All Natural Medicine Clinic, LLC (1) · Attenua, Inc. (1)
United Kingdom (25) · United States (24) · Canada (11) · Netherlands (7) · Germany (6) · Poland (5) · Australia (4) · China (4) · Czechia (4) · Taiwan (4) · Hungary (3) · Italy (3) · Japan (3) · New Zealand (3) · Spain (3)
Vivek N Iyer, MD (2) · Ahmet Tutuncu, MD, PhD (1) · Alexandra E. Brandimore, M.A. (1) · Alexandra E. Brandimore, M.A. CCC/SLP (1) · Alyn H Morice (1) · Amanda Gillespie, PhD (1) · Ardi Zulfariansyah, MD (1) · Ashley Woodcock, Prof. (1)
PMID 15966463, PMID 19029430, PMID 19937046, PMID 25467586, PMID 25811287, PMID 27130637, PMID 28923239, PMID 31023843, PMID 31949115, PMID 32109425, PMID 33825965, PMID 33986030, PMID 34152585, PMID 34697975, PMID 35614875, PMID 35624408, PMID 36345090, PMID 36348054, PMID 36512069, PMID 37041539, PMID 37261531, PMID 38044419, PMID 38320144, PMID 40043302, PMID 40498172, PMID 41569557, PMID 42548348
2015 (4), 2017 (3), 2016 (2), 2018 (2), 2019 (2), R34HL132369 (1)